Abstract Fibroblast growth factors (FGFs) and their receptors (FGFRs) are transmembrane growth factor receptors with wide tissue distribution. FGF/FGFR signaling is involved in neoplastic behavior and also development, differentiation, growth, and survival. FGFR germline mutations (activating) can cause skeletal disorders, primarily dwarfism (generally mutations in FGFR3), and craniofacial malformation syndromes (usually mutations in FGFR1 and FGFR2); intriguingly, some of these activating FGFR mutations are also seen in human cancers. FGF/FGFR aberrations reported in cancers are mainly thought to be gain-of-function changes, and several cancers have high frequencies of FGFR alterations, including breast, bladder, or squamous cell carcinomas (lung and head and neck). FGF ligand aberrations (predominantly gene amplifications) are also frequently seen in cancers, in contrast to hereditary syndromes. There are several pharmacologic agents that have been or are being developed for inhibition of FGFR/FGF signaling. These include both highly selective inhibitors as well as multi-kinase inhibitors. Of note, only four agents (ponatinib, pazopanib, regorafenib, and recently lenvatinib) are FDA-approved for use in cancer, although the approval was not based on their activity against FGFR.
Introduction
One of the most important advances in tumor biology is the recognition that cancer is frequently driven by inherited or acquired alterations in specific gene(s) or their products [1, 2] . Genomic alterations include changes in expression that can result from mutation, deletion, gene amplification, and/ or translocation. Complicating matters, cancers often harbor multiple genetic alterations, but one or a few of these are thought to be primarily responsible for neoplastic behavior in any given tumor. These are the so-called Bdriver mutations,^while Bpassenger mutations^may have a more nuanced impact. A literature review suggests that over 1 % of human genes can be implicated as cancer drivers when they are mutated, with protein kinases comprising the largest subgroup of genes altered [3] .
Among human signaling pathways, fibroblast growth factor (FGF)/fibroblast growth factor receptor (FGFR) is one of the pathways most enriched in non-synonymous mutations, including several candidate driver mutations [3] . A computational method designed to identify driver mutations within protein kinase datasets successfully identified multiple aberrations in the FGF/FGFR machinery [4] . In keeping with other genes implicated in neoplastic behavior, FGF/FGFR signaling is also involved in development, differentiation, growth, and Most of the reported FGFR mutations that cause heritable human diseases are activating mutations which increase receptor signaling. These abnormalities are seen in craniofacial and skeletal syndromes such as the craniosynostoses [5] [6] [7] (Pfeiffer, Crouzon, Apert, Jackson-Weiss, Muenke, and Beare-Stevenson syndromes) and dwarfism syndromes [8, 9] ( a c h o n d r o p l a s i a , t h a n a t o p h o r i c d y s p l a s i a , a n d hypochondroplasia). The only reported inherited condition caused by loss of FGFR function is an autosomal dominant form of hereditary hypogonatotrophic hypogonadism 2 with or without anosmia [10, 11] , which is caused by loss of function of FGFR1 [10, 12, 13] or a missense mutation in FGF8 [14] . Intriguingly, some of the same activating FGFR mutations seen in inherited syndromes are also seen in human cancers [14, 15] . Furthermore, FGF/FGFR aberrations reported in cancers are overwhelmingly thought to be gain-offunction changes, including gene amplifications and gene rearrangements [16] .
The goal of identification and characterization of driver mutations in cancer is, ultimately, to create successful anticancer therapies with which to prosecute these tumors; several such therapies already exist, demonstrating proof of principle [17, 18] . Furthermore, for some gene targets, drugs may impact the course of cancer as well as non-malignant conditions that are driven by abnormalities in the cognate signal. JAK2 aberrations, for instance, are found in myelofibrosis, and JAK2 inhibitors such as ruxolitinib provide significant benefit in such patients [19] . At the same time, the JAK2 inhibitor tofacitinib can benefit patients with rheumatoid arthritis and is approved for that indication [20] . In the case of FGF/FGFR, multiple drugs targeting this pathway have entered the clinic [16] . Herein, we discuss the landscape of diseases that are driven by aberrant FGF/FGFR machinery.
Molecular biology of FGF/FGFR signaling
Fibroblast growth factors (FGFs) and their receptors (FGFRs) are evolutionarily conserved transmembrane growth factor receptors with wide tissue distribution in all vertebrates. FGFs and FGFRs share homologies among their respective groups and with other signaling molecules. FGFRs in particular are similar to other signaling receptors, including vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and other receptor tyrosine kinases [21] . However, there are important differences between the individual signaling molecules that allow for precise control of a full range of processes, including development, cell survival, differentiation, motility, angiogenesis, and carcinogenesis.
Receptors
In humans, there are five known FGFRs, called FGFR1-FGFR4 and FGFRL1 (also known as FGFR5). FGFR1-FGFR4 are typical growth factor receptor tyrosine kinases, with extracellular immunoglobulin (Ig)-like domains and intracellular tyrosine kinase domains, while FGFRL1 lacks the intracellular kinase domain and has less clear function(s) [22, 23] . Upon binding of their ligands, the typical receptors homo-or hetero-dimerize, leading to sequential phosphorylation of specific intracellular tyrosine residues and activation of an intracellular signaling cascade and gene transcription [24] (Fig. 1) . The FGFR signaling pathway interacts with several other important intracellular pathways, including PI3K/Akt, Wnt, hedgehog, and bone morphogenic protein (BMP) [24, 25] . FGFR1-4 have different ligand specificities based on developmental aspects, tissue distribution, and RNA splicing variation [26] . For example, the FGFR2b isoform is predominantly expressed in epithelial cells, while the FGFR2c isoform is expressed predominantly in mesenchymal cells, and switching from FGFR2b to FGFR2c occurs during progression and invasion of prostate and bladder cancers [27] .
Ligands
There are 18 human ligands for FGFRs (Fig. 1) . They are FGF1 (acidic FGF), FGF2 (basic FGF), FGF3, FGF4,  FGF5, FGF6, FGF7 (KGF), FGF8, FGF9, FGF10, FGF16,  FGF17, FGF18, FGF19, FGF20, FGF21, FGF22, and  FGF23. FGF11-14 are not ligands for FGFRs and are known  as FGF homologous factors (FHF1-4) [28, 29] . There is no human FGF15 (FGF15 is the mouse equivalent of human FGF19) [30] . The FGFR ligands are secreted proteins that bind to the extracellular matrix, thereby restricting their influence to the tissue where they are produced (autocrine or paracrine function). However, three of the FGFs-FGF19, FGF21, and FGF23-bind less tightly to extracellular matrix heparin sulfates, so they are able to act systemically in an endocrine fashion (hormone-like), allowing them to spread from their production site into the circulation [30, 31] . Most FGFs are secreted proteins with cleavable amino terminal portions, but FGF9, FGF16, and FGF20 have non-cleavable secretion sequences, and FGF1 and FGF2 have no secretion sequences, although they are found in the extracellular compartment, suggesting an alternate process of release [29, 32] . Most FGFs are released from binding to the extracellular matrix via action of heparin sulfate proteoglycans and/or fibroblast growth factor-binding protein (FGFBP1) [33] .
FGF/FGFR interaction and function
In general, FGFs are promiscuous, and most can bind to any of the four main FGFRs, although some of the FGF/FGFR ligand/receptor pairs differ in their affinities (Fig. 1c) . FGFs interact with cell surface heparan sulfate proteoglycans (HSPGs) and with the transmembrane protein Klotho (for the hormone-like FGF19, 20, 23) to stabilize binding to FGFRs. Ornitz et al. [34, 35] systemically investigated affinities of FGFs for each FGFR isoform and showed, for example, that FGFR2b is a high-affinity receptor for FGF1, FGF7, FGF10, and FGF22, while FGFR2c has high affinity for FGF1, FGF2, FGF4, FGF6, FGF8, FGF9, and FGF20. But, differential expression of either FGFs or FGFRs in time or tissue may also contribute to tissue-specific effects of FGF/ FGFR signaling. For example, FGF1 and FGF2 are expressed in both embryonic and adult tissues, while FGF7-FGF9 are predominantly expressed in developing or in restricted adult tissues [36] .
The differences in activity/function of the different FGF/ FGFR pairs are also highlighted by murine gene knockout experiments. Mice heterozygous for FGFR knockout mutations develop normally, so haplo-insufficiency is not likely to be a factor [37] . However, mice homozygous for FGFR1 or FGFR2 null mutations die in utero, and FGFR3-null mice develop normally other than overgrowth of cancellous bones and deafness [37] . Most of the FGFs have also been knocked out in mouse models, with varying phenotypic effects, including lethality (FGF4, FGF8, FGF9, FGF10, FGF19, FGF18, and FGF23), defects in neuromusculoskeletal development or function (FGF2, FGF3, FGF6, FGF7, FGF12, FGF14, FGF17, FGF18), cardiac defects (FGF2, FGF9, FGF16, FGF19), and no identifiable abnormality (FGF1) [29] .
Activation of signaling
To signal, FGFs have to be released from the extracellular matrix by heparinases, proteases, or specific fibroblast growth factor-binding protein (FGFBP1). FGFBP1 are secreted [71] . c The interactions between FGFs and FGFRs; references: Guillemot et al. [32] , Powers et al. [191] , Ornitz et al. [192] , Zhang et al. [34] . Interaction between FGF ligands and receptors is an evolving field; variability may be observed between studies and tissue types. heparin proteins that reversibly bind FGF1 and FGF2, releasing them from the extracellular matrix and increasing the local levels of free ligand available for receptor binding [38] . FGFBP1 is secreted by keratinocytes and human epidermal carcinomas, particularly squamous cell carcinomas [33, 38] . Its expression is seen in development, wound healing, cancer, and angiogenesis, and it is downregulated by pharmacologic agents in vitro [33] . The fibronectin-leucine-rich transmembrane protein 3 (FLRT3) is co-expressed with FGF8 during development, co-immunoprecipitates with FGF8/FGFRs, physically interacts with FGFRs via its fibronectin type III domain, and increases activity through the MAPK pathway, facilitating FGFR signaling [39, 40] .
Inhibition of signaling
FGF/FGFR signaling is negatively regulated by several mechanisms. FGFR stimulation activates sprouty proteins (SPRY1-4), which in turn negatively feedbacks on FGF/ FGFR/MAPK signaling by interacting with growth factor receptor bound protein 2 (GRB2), son of sevenless homolog 1 (SoS1), and/or RAF proto-oncogene serine/threonine-protein kinase (RAF1) [41, 42] . Intriguingly, sprouty proteins are thought to be general inhibitors of receptor tyrosine kinase growth factor signaling via inhibition of Ras-MAPK signaling, but their behavior differs among specific growth factor receptors. For example, sprouty protein inhibits FGFR signaling but potentiates epidermal growth factor receptor (EGFR) signaling [43] . The cytoplasmic domain of similar expression to FGF (SEF, also known as IL-17 receptor D) interacts with the cytoplasmic domain of FGFR and inhibits downstream signaling of the pathway [43] . Finally, MAP kinase phosphatases (MKPs) dephosphorylate ERKs and thereby downregulate the signaling pathway. MKP3 functions within the cytoplasm, whereas MKP1 is localized in the nucleus [43] . FGFRL1 is the atypical receptor that lacks an intracellular kinase domain. Like the other FGFRs, it is found in all vertebrates, is expressed in a wide variety of tissues, and binds to some FGF ligands. In vitro experiments show that FGFRL1 binds FGF3, FGF4, FGF8, FGF10, and FGF22, but not the other FGFs tested [44] . Unlike FGFR1-4, it is shed from cell membranes [44] , suggesting that it may serve as a ligand trap to negatively regulate signaling [45] . Other regulatory mechanisms might include heterodimerization with other FGFRs to prevent trans-autophophorylation and thereby negatively regulating intracellular signaling or by increasing membrane turnover rates of the other FGFRs, but there is currently no evidence that these mechanisms exist [45] . The exact functions of FGFRL1 are not known. FGFRL1-null mice die in infancy with diaphragmatic defects and renal agenesis [45] , and there are case reports of FGFRL1 mutations in human disease: craniosynostosis [46] and ovarian cancer [47] .
FGF/FGFR aberrant signaling in human disease

Inherited syndromes
Several types of inherited syndromes are due to germline aberrations in FGFR. These include craniosynostosis syndromes and achondroplasia [48] , mainly due to gain-of-function mutations, as well as loss-of-function anomalies associated with congenital hypogonadotropic hypogonadism (Table 1) . Interestingly, although some of these aberrations are identical to those that, in somatic form, are associated with cancer, for the most part, the individuals with these hereditary syndromes have not been reported to have an increased incidence of cancer. Apart from case reports [49] [50] [51] [52] [53] , there is no epidemiologic evidence that people with craniosynostosis, dwarfism, or congenital hypogonadotropic hypogonadism are at increased risk for malignancy. This is possibly related to differential effects of activating FGFR mutations in cell or tissue type in the context of stage of development. It is possible, for instance, that there are as yet unknown anti-neoplastic compensatory effects in individuals with these disorders, perhaps stemming from the presence of germline FGFR aberrations during development as opposed to the appearance of somatic FGFR mutations in human cancers.
Somatic aberrations in benign conditions
Somatic or acquired mutations in FGFR3 have been observed in benign skin conditions like seborrheic keratosis and epidermal nevi [54, 55] . These aberrations are activating and, when evaluated, are not seen in adjacent normal skin [55] . Many of these are identical to mutations that are also seen in bladder and/or cervical cancers.
Somatic aberrations in malignancies
Aberrations in FGFR and its ligands are common in malignancy (Tables 2, 3 , and 4 and Figs. 2 and 3 ). Across malignancies, FGF anomalies are found in ≈14 % and FGFR in ≈7 % of malignancies [56] (FGF/FGFR in about 20 %).
FGFR alterations
While almost any FGFR genes can be altered in many cancer types, some acquired genetic aberrations are more striking in prevalence or in cancer type(s) than others. The most common abnormalities reported to date are gene amplifications of FGFR1-3 ( Table 2 ). These are generally assumed to represent activation or gain-of-function amplifications, but full molecular characterization of the effects of gene amplification within specific cellular or cancer microenvironment contexts is not fully available. The cancers in which FGFR gene amplifications are most frequent include bladder urothelial carcinomas (FGFR1), squamous cell lung cancer (FGFR1), head and neck squamous cell cancer (FGFR1), uterine carcinosarcoma (FGFR3), breast adenocarcinoma (FGFR1), and gastric adenocarcinoma (FGFR2) ( Tables 2 and 3 , and Fig. 2 ). In fact, FGFR2 was first identified in a gastric cancer cell line, and it is preferentially amplified/overexpressed in the diffuse type of gastric cancer, which correlates with poor prognosis, at least in a Japanese population [57] . More commonly, however, mutations in FGFR3 characterize bladder carcinoma. Indeed, activating mutations of fibroblast growth factor receptor-3 (FGFR3) have been described in approximately 75 % of low-grade papillary bladder tumors. In muscle-invasive disease, FGFR3 mutations are found in 20 % of tumors, but overexpression of FGFR3 is observed in about half of cases [58] . Loss-of-function alterations are relatively uncommon in cancer (a pattern that is also seen in hereditary disorders). However, there is at least one report indicating that some melanoma cell lines demonstrate FGFR2 loss of function [59] .
FGFR1 amplification is prevalent in both squamous cell carcinoma of the lung and of the head and neck, suggesting a possible common underlying mechanism of carcinogenesis in these smoking-related carcinomas. Perhaps more importantly, development of FGFR1 inhibitors represents a viable targeted therapy for use in squamous cell lung cancers [60, 61] .
FGF alterations
FGF abnormalities are for the most part amplifications (Fig. 3 and Table 4 ). There are few reported data regarding the mechanism(s) of action of these amplifications. Nevertheless, it seems reasonable to hypothesize that abundance of ligand could lead to increased receptor signaling, but the reality may be more complex, perhaps relating to the stoichiometric proportions of the different ligands present. Of note, three of the ligands, FGF3, FGF4, and FGF19, are frequently coamplified on 11q13 [62] . This amplicon is present in several cancers, including breast, bladder, and squamous cell carcinoma of the lung and head and neck ( Fig. 3 and Table 4 ).
FGFR rearrangements
Chromosomal translocation gives rise to chimeric gene products with aberrant function (Table 2 ). In general, fusion gene proteins result from the fusion of a Bpartner gene^with a tyrosine kinase domain derived from the FGFR family member gene. As a result of their constant dimerization state, they are constitutively active in the absence of ligand. The FGFR1 gene can be fused to other genes including BCR, ZNF198, CEP110, FGFR1OP1, FGFR1OP2, HERVK, TRIM24, LRRFIP1, and MYO18A, in the 8p11 myeloproliferative syndrome manifested by myeloproliferative neoplasms and peripheral blood eosinophilia without basophilia [63] ; it is fused to the FOXO1 gene in alveolar rhabdomyosarcoma, and the FOXO1-FGFR1 fusion gene is amplified [64] . The FGFR3 gene is fused to the MMSET gene as a result of a t(4;14)(p16.3;q32) chromosomal translocation in 10-20 % of multiple myeloma [65] ; it is fused to the ETV6 gene in peripheral T cell lymphoma with a t(4;12)(p16;p13) chromosomal translocation [66] . In glioblastoma multiforme, FGFR1 and FGFR3 genes are fused to neighboring TACC1 and TACC3 genes due to interstitial deletions, respectively [67, 68] .
FGF/FGFR signaling inhibitors and cancer therapy 4.1 FDA approved drugs that target FGFR
Only four drugs (ponatinib, regorafenib, pazopanib, and more recently lenvatinib) are FDA-approved for use in human cancers (Table 5) . Ponatinib is a multi-tyrosine kinase inhibitor that was approved for imatinib-resistant chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (CP) acute lymphoblastic leukemia (ALL). The efficacy results Regorafenib, and its active metabolites inhibit multiple membrane-bound and intracellular kinases including those in the RET, VEGFR1, VEGFR2, VEGFR3, KIT, PDGFR-α and -β, FGFR1-2, and Abl pathways. Pazopanib was approved for advanced renal cell carcinoma (based on a progression-free survival of 9.2 months compared to 4.2 months in the placebo arm), as well as soft tissue sarcomas (improved progression-free survival: 4.6 months versus 1.6 for patients who received placebo). Pazopanib is a multi-tyrosine kinase inhibitor whose targets include VEGFR1-3, PDGFR-α and -β, FGFR-1 and -3, and KIT. Lastly, lenvatinib is a multi-kinase inhibitor (targets including VEGFR1-3, FGFR1-4, PDGFR-α, KIT, and RET) indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. The recent approval in February 2015 was based on an improved progression-free survival (18.3 vs 3.6 months in the placebo group, P<0.001). The approvals of these four agents (ponatinib, regorafenib, pazopanib, and lenvatinib), all three of which are multi-kinase inhibitors, were not based on activity against FGFR. Of interest, nintedanib is an FGFR inhibitor that is FDA-approved for a non-cancer indication-idiopathic pulmonary fibrosis (Table 5 ).
Experimental agents that target FGF/FGFR
There are several pharmacologic agents that have been or are being developed for inhibition of FGFR via targeting of the ATP binding site of the intracellular tyrosine kinase domain(s) ( Table 5 ). The inhibition varies by their affinities for FGFR signaling, as most of these molecules are promiscuous kinase inhibitors (inhibiting VEGF, PDGF, and many other TKIs in addition to FGFR). Figure 1b gives examples of selective versus non-selective FGFR inhibitors. Of note, the dual kinase inhibitor (VEGFR/FGFR) lucitanib has shown activity in FGFR1-amplified breast cancer, with an overall response rate of 50 % [69] . There are also selective tyrosine kinase inhibitors (TKIs) available (Table 5 and Fig. 1b) . While several of these agents are currently in clinical trials, none of the more highly selective FGFR inhibitors (e.g., BGJ398 or AZD4547) are currently FDA-approved. A recent study demonstrated that Debio 1347 (a selective orally available FGFR1-3 inhibitor) displayed preferential anti-tumor activity against cells The IC 50 (half-maximal inhibitory concentration) was <100 nmol/L for all the drugs included, except regorafenib FGFR fibroblast growth factor receptor, GIST gastrointestinal stromal tumor with FGFR genetic alterations in a panel of 327 cancer cell lines and xenograft models [70] . Debio 1347 is currently under investigation for the treatment of patients harboring FGFR genetic alterations. Of interest, other types of agents have been developed. As an example, FP-1039 is a soluble fusion protein, consisting of the extracellular domains of human FGFR1 linked to the Fc region of the human immunoglobulin G1; it is designed to bind multiple FGF ligands [71] (TRAP molecule) .
A large number of other drugs and indications are being pursued. Some FGFR inhibitors have failed to meet their phase III endpoints ( Table 5 ). The majority of the failed trials, however, have been performed in patient populations that were not biomarker-selected.
Resistance mechanisms
In a recent phase 1 study reporting on patients with FGFR1-amplified (identified by fluorescent/chromogenic in situ hybridization) advanced or metastatic lung squamous cell carcinoma (SCC) treated with the selective pan-FGFR inhibitor BGJ398, only a limited number of patients achieved relatively short-lived partial responses (2 of 17 patients, 11.7 %); responses lasted 3 and 8 months. These observations suggest the existence of resistance mechanisms. Sohl et al. [72] reported that resistance mutations at the Bgatekeeper^residue may arise (FGFR1 V561M mutation confers a 38-fold increase in autophosphorylation and significant resistance to lucitanib), leading to tumor progression and explaining the non-durable responses. For instance, it has also been shown that the heterozygous gatekeeper mutation FGFR3 V555M appeared as a mechanism of acquired resistance to selective FGFR inhibitors [73] . Several other activating mutations were identified in FGFR2-expressing cells treated with high concentrations of dovitinib, and the multi-kinase inhibitor ponatinib inhibitory activity was affected by the V565I gatekeeper mutation [74] . In addition, a previously undescribed FGFR3 variant was identified as a key contributor to resistance in the MGH156-1A cell line derived from a patient with acquired resistance to EGFR TKIs [75] , and follow-up studies clearly indicated that FGFR inhibitors re-sensitized these cells to EGFR inhibitors.
Besides secondary mutations in the kinase domain, resistance to FGFR kinase inhibitors may also occur through activation of alternative signaling pathways, as demonstrated by Harbinski et al. [76] who showed a broad and versatile potential for tyrosine kinase receptor from the FGFR, HER, and MET family to compensate for each other. Javidi-Sharifi et al. [77] suggest that some patients with gastrointestinal stromal tumor (GIST) treated with imatinib can develop a functional dependence on FGFR3, illustrated by the fact that the addition of the FGFR3 ligand FGF2 to GIST cells restored KIT phosphorylation during imatinib treatment. Furthermore, signaling crosstalk between KIT and FGFR3 activated the MAPK pathway to promote resistance to imatinib. FGFR amplification and overexpression have also been related to poor prognosis and endocrine resistance in breast cancer [78] . Of note, relationships between cyclins and FGF/FGFRs have also been reported at the protein level. For instance, a study showed that FGFR4 contributed to the maintenance of CCND1 via the mTOR translation pathway, and several other studies demonstrated cooperation between FGFR and CCND1 [79] . Finally, most patients with advanced cancer have complex molecular portfolios, and hence there may be multiple genomic drivers that are active and supplant the role of FGFR [80] [81] [82] . In that context, it appears evident that identification of resistance mechanisms is crucial to crafting effective drug combinations.
Conclusion
The FGF/FGFR pathway is crucial to a variety of human diseases. There are five known FGFRs, FGFR1-FGFR4 and FGFRL1, and 18 human ligands for FGFRs. FGFR germline mutations (activating) can cause skeletal disorders, primarily dwarfism (generally mutations in FGFR3) and craniofacial malformation syndromes (usually mutations in FGFR1 and FGFR2). Loss-of-function mutations in FGF signaling are seen in congenital hypogonadotropic hypogonadism (including the Kallman syndrome variant with anosmia). Interestingly, many of the aberrations that cause the inherited skeletal disorders are also seen in human cancers.
The most common abnormalities in malignancies are gene amplifications of FGFR1-3 or of the FGF ligands. The cancers in which FGFR gene amplifications are most frequent include squamous cell lung cancer (FGFR1), head and neck squamous cell cancer (FGFR1), bladder (transitional cell) cancer (FGFR1), endometrial cancer (FGFR1), gastric adenocarcinoma (FGFR2), breast adenocarcinoma (FGFR1), and prostate adenocarcinoma (FGFR1). Point mutations are seen in all FGFRs but are less frequent in FGFs. For instance, mutations in FGFR3 are frequent in bladder carcinoma, and FGFR2 mutations in endometrial cancer, melanoma, and gastric tumors (Tables 2 and 3) .
Interestingly, somatic mutations in FGFR3 have been observed in benign skin conditions such as seborrheic keratosis and epidermal nevi (but not in adjacent normal skin) [54] . FGFR rearrangements are also observed in certain cancers and characterize certain myeloproliferative disorders (Table 2) .
Importantly, there are several pharmacologic agents that have been or are being developed for inhibition of FGFR kinases. These include both highly selective inhibitors as well as multi-kinase inhibitors. Ponatinib, regorafenib, pazopanib, and lenvatinib are already FDAapproved for cancer, albeit not on the basis of their FGFR activity. Very few studies in cancer have been aimed at an FGFR biomarker-selected population, and several of the FGFR inhibitors have failed phase III studies in unselected patients. A multi-kinase inhibitor (nintedanib), which suppresses FGFR1-3, was also recently FDA-approved for idiopathic pulmonary fibrosis.
Whether or not FGFR inhibitors could also be used to moderate the phenotype of inherited disorders due to FGFR activation is an intriguing question. Of interest, Garcia et al. [48] injected ia mouse model of achondroplasia with a soluble form of human FGFR3 (acting as a decoy receptor and preventing FGF from binding to mutant FGFR3), and effective maturation of growth plate chondrocytes was restored in the bones of treated mice. Of interest in this regard, individuals afflicted with the inherited disorders associated with FGFR aberrations, such as dwarfism, do not have an increased incidence of cancer, despite having mutations that are often identical to those somatic FGFR aberrations that characterize certain tumors. The secondary modulatory influences that mitigate the risk of cancer in these individuals are of interest. Whether or not treating them at an early age with FGFR inhibitors would increase the later risk of cancer if the inhibitors were withdrawn would need to be considered.
In summary, perturbations in the FGF/FGFR machinery appear to underlie a variety of inherited syndromes, as well as benign and malignant disorders. The advent of potent FGFR inhibitors provides important new agents in the armamentarium against diseases caused by FGF/FGFR abnormalities.
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